Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

PI3K plays a key role in cellular metabolism and cancer. Using a mass spectrometry-based metabolomics platform, we discovered that plasma concentrations of 26 metabolites, including amino acids, acylcarnitines, and phosphatidylcholines, were decreased in mice bearing PTEN-deficient tumors compared w...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ang, Joo Ern, Pandher, Rupinder, Ang, Joo Chew, Asad, Yasmin J, Henley, Alan T, Valenti, Melanie, Box, Gary, de, Haven Brandon Alexis, Baird, Richard, Friedman, Lori, Derynck, Mika, Vanhaesebroeck, Bart, Eccles, Suzanne A, Kaye, Stan B, Workman, Paul, de, Bono Johann S, Raynaud, Florence I
Autres auteurs: Antwerp X-ray Analysis, Electrochemistry and Speciation (AXES)
Langue:anglais
Publié: American Association for Cancer Research 2019
Accès en ligne:https://demo7.dspace.org/handle/123456789/449
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires: Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation